Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
144.83
+13.16 (9.99%)
At close: Apr 28, 2026, 4:00 PM EDT
145.34
+0.51 (0.35%)
After-hours: Apr 28, 2026, 6:40 PM EDT
Revolution Medicines Employees
Revolution Medicines had 883 employees as of December 31, 2025. The number of employees increased by 349 or 65.36% compared to the previous year.
Employees
883
Change (1Y)
349
Growth (1Y)
65.36%
Revenue / Employee
n/a
Profits / Employee
-$1,281,202
Market Cap
30.46B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| BeOne Medicines AG | 12,000 |
| BioNTech SE | 7,807 |
| Moderna | 4,700 |
| Genmab | 2,973 |
| Incyte | 2,844 |
| Alnylam Pharmaceuticals | 2,500 |
| argenx SE | 1,863 |
| Insmed | 1,664 |
RVMD News
- 13 hours ago - There's a Revolution in Cancer. But Can Big Pharma Afford It? - WSJ
- 7 days ago - Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting - GlobeNewsWire
- 7 days ago - Two experimental drugs showed striking early results against pancreatic cancer - WSJ
- 7 days ago - Revolution Medicines to Present Preclinical Data on Innovative Mutant-Targeted Catalytic RAS(ON) Inhibitor at the 2026 AACR Annual Meeting - GlobeNewsWire
- 7 days ago - Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual Meeting - GlobeNewsWire
- 9 days ago - Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual Meeting - GlobeNewsWire
- 11 days ago - Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 11 days ago - Top 2 Health Care Stocks That May Fall Off A Cliff In Q2 - Benzinga